⚠️ NOT FOR HUMAN CONSUMPTION – FOR RESEARCH PURPOSES ONLY ⚠️ ARA‑290 (Cibinetide)A synthetic 11-amino-acid peptide derived from the helix B region of erythropoietin, engineered to selectively activate the innate repair receptor (IRR)—a receptor complex combining the erythropoietin receptor and β-common receptor—to promote tissue repair and reduce inflammation without erythropoietic effects. Form: Lyophilized powder Purity: >98% (HPLC) Storage: Store in a cool, dry, and dark environment; long-term storage typically at –20 °C(Sources: Brines et al. review – peptide design & effects, Wikipedia – Cibinetide overview) Research Highlights Demonstrated tissue-protective and anti-inflammatory effects in numerous preclinical models—such as diabetic retinopathy, neuropathy, myocardial infarction, and traumatic injury—by engaging the IRR and averting pro-inflammatory cytokine activity.(Sources: Brines et al. summary, Suppl. analgesic mechanism via TRPV1 inhibition, Pain Reports on IRR activation) In early human trials, ARA‑290 improved metabolic markers and alleviated neuropathic symptoms—including enhanced corneal nerve fiber density and improved HbA1c and lipid profiles—in patients with type 2 diabetes and small fiber neuropathy.(Sources: Brines et al. clinical study (type 2 diabetes), Weill Cornell overview) Emerging research in animal models suggests antidepressant-like effects, as ARA‑290 was shown to reduce stress-induced depressive behaviors, potentially via anti-inflammatory pathways.(Source: 2022 study in mice on mood modulation) This compound is strictly intended for laboratory research use only.It is not approved for human or veterinary use, not a dietary supplement, and must not be used to diagnose, treat, cure, or prevent any disease or condition. FOR LABORATORY USE ONLY. NOT FOR HUMAN CONSUMPTION.